Bristol-myers Squibb Co. Share Price (NYSE: BMY)

$46.94

▲

0.06

(0.13%)

Live

Last updated on August 30, 2025 at 12:43 am IST

$₹

Check the interactive Bristol-myers Squibb Co. Stock chart to analyse performance

Bristol-myers Squibb Co. stock performance

as on August 30, 2025 at 12:43 am IST

Today's Low:$46.84
Today's High:$47.32
$46.94
0.21%
Downside
Day's Volatility :1.01%
Upside
0.8%
52 Weeks Low:$42.96
52 Weeks High:$63.33
$46.94
8.48%
Downside
52 Weeks Volatility :32.16%
Upside
25.88%

Bristol-myers Squibb Co. Stock Returns

Period	Bristol-myers Squibb Co.	Sector (Health Care)	Index (Russel 2000)
3 Months	-2.9%	3.1%	0.0%
6 Months	-21.37%	-8.4%	0.0%
1 Year	-5.71%	-12.6%	0.0%
3 Years	-30.24%	7.9%	-6.1%

Bristol-myers Squibb Co. Key Stats

Check Bristol-myers Squibb Co. key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$46.88
Open	$47.52
Today's High	$47.32
Today's Low	$46.84
Market Capitalization	$95.4B
Today's Volume	$7.9M
52 Week High	$63.33
52 Week Low	$42.96
Revenue TTM	$47.7B
EBITDA	$19.1B
Earnings Per Share (EPS)	$2.49
PE Ratio	18.83
Dividend Yield	5.16%
Profit Margin	10.58%
Quarterly Earnings Growth YOY	-0.23%
Return On Equity TTM	29.32%

Stock Returns calculator for Bristol-myers Squibb Co. Stock including INR - Dollar returns

The Bristol-myers Squibb Co. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Bristol-myers Squibb Co. investment value today

Current value as on today

₹99,728

Returns

₹272

(-0.27%)

Returns from Bristol-myers Squibb Co. Stock

₹5,591 (-5.59%)

Dollar Returns*

₹5,319 (+5.32%)

Indian investors sentiment towards Bristol-myers Squibb Co. Stock

-6.25%

Period: Jul 29, 2025 to Aug 28, 2025. Change in 30 Days versus previous period

Investment in Bristol-myers Squibb Co. Shares from India has dropped by -6.25% over the past 30 days, indicating reduced transactional activity.

Period: Jul 29, 2025 to Aug 28, 2025. Change in 30 Days versus previous period

Search interest for Bristol-myers Squibb Co. Stock from India on INDmoney has increased by 6% in the last 30 days, reflecting an upward trend in search activity.

Indian Mutual Funds that invest in Bristol-myers Squibb Co. Stock

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	16450	-707.68	0.16%
ICICI Prudential US Bluechip Equity Fund Direct Plan Growth	97849	48155.41	1.14%

Global Institutional Holdings in Bristol-myers Squibb Co.

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
9.58%
BlackRock Inc
7.93%
JPMorgan Chase & Co
5.31%
State Street Corp
4.66%
Charles Schwab Investment Management Inc
3.48%
Capital Research & Mgmt Co - Division 3
3.25%

Analyst Recommendation on Bristol-myers Squibb Co. Stock

Rating

Trend

Hold

32%Buy

64%Hold

3%Sell

Based on 31 Wall street analysts offering stock ratings for Bristol-myers Squibb Co.(by analysts ranked 0 to 5 stars)

Bristol-myers Squibb Co. Share Price Target

What analysts predicted

Upside of 12.91%

Target:

$53.00

Current:

$46.94

Bristol-myers Squibb Co. share price target is $53.00, a slight Upside of 12.91% compared to current price of $46.94 as per analysts' prediction.

Bristol-myers Squibb Co. Stock Insights

Price Movement
In the last 6 months, BMY stock has moved down by -21.4%
Increasing Revenue
Bristol-Myers Squibb Co. has shown positive revenue growth over the last two quarters. The revenue increased from $11.20 billion to $12.26 billion, reflecting an average increase of 8.7% per quarter.
Decreasing Net Profit
Bristol-Myers Squibb Co. has experienced a decline in net profit over the past two quarters. The net profit dropped significantly from $2.45 billion to $1.31 billion, averaging a decrease of 46.7% each quarter.
BMY vs JNJ (1 yr)
In the last 1 year, Johnson & Johnson has given 6.8% return, outperforming this stock by 12.5%
BMY vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 7.6% return, outperforming this stock by 37.4%
Price to Sales
Bristol-Myers Squibb Co. has a Price-to-Sales (P/S) Ratio of 2.0, meaning that investors are willing to pay $2.00 for every $1.00 of sales. In comparison, Johnson & Johnson has a higher P/S Ratio of 4.7, indicating that investors are willing to pay more for its sales. This suggests that Bristol-Myers Squibb is valued less by investors relative to its sales when compared to Johnson & Johnson.

Bristol-myers Squibb Co. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$26.1B	↑ 15.89%
Net Income	$3.4B	↓ 30.1%
Net Profit Margin	13.15%	↓ 8.66%

	FY20	Y/Y Change
Revenue	$42.5B	↑ 62.62%
Net Income	$-9.0B	↓ 361.56%
Net Profit Margin	-21.16%	↓ 34.31%

	FY21	Y/Y Change
Revenue	$46.4B	↑ 9.09%
Net Income	$7.0B	↓ 177.75%
Net Profit Margin	15.08%	↑ 36.24%

	FY22	Y/Y Change
Revenue	$46.2B	↓ 0.49%
Net Income	$6.3B	↓ 9.54%
Net Profit Margin	13.71%	↓ 1.37%

	FY23	Y/Y Change
Revenue	$45.0B	↓ 2.5%
Net Income	$8.0B	↑ 26.84%
Net Profit Margin	17.83%	↑ 4.12%

	FY24	Y/Y Change
Revenue	$48.3B	↑ 7.32%
Net Income	$-8.9B	↓ 211.5%
Net Profit Margin	-18.53%	↓ 36.36%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$11.9B	↑ 3.38%
Net Income	$-11.9B	↓ 775.99%
Net Profit Margin	-100.39%	↓ 115.74%

	Q2 FY24	Q/Q Change
Revenue	$12.2B	↑ 2.83%
Net Income	$1.7B	↓ 114.1%
Net Profit Margin	13.77%	↑ 114.16%

	Q3 FY24	Q/Q Change
Revenue	$11.9B	↓ 2.53%
Net Income	$1.2B	↓ 27.92%
Net Profit Margin	10.18%	↓ 3.59%

	Q4 FY24	Q/Q Change
Revenue	$12.3B	↑ 3.78%
Net Income	$72.0M	↓ 94.05%
Net Profit Margin	0.58%	↓ 9.6%

	Q1 FY25	Q/Q Change
Revenue	$11.2B	↓ 9.24%
Net Income	$2.5B	↑ 3311.11%
Net Profit Margin	21.93%	↑ 21.35%

	Q2 FY25	Q/Q Change
Revenue	$12.3B	↑ 9.53%
Net Income	$1.3B	↓ 46.66%
Net Profit Margin	10.68%	↓ 11.25%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$17.3B	↑ 7.31%

	FY20	Y/Y Change
Profit	$21.7B	↑ 25.8%

	FY21	Y/Y Change
Profit	$26.8B	↑ 23.32%

	FY22	Y/Y Change
Profit	$26.5B	↓ 1.01%

	FY23	Y/Y Change
Profit	$25.4B	↓ 4.28%

	FY24	Y/Y Change
Profit	$27.4B	↑ 8.18%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$6.6B	↑ 1.51%

	Q2 FY24	Q/Q Change
Profit	$6.8B	↑ 3.2%

	Q3 FY24	Q/Q Change
Profit	$6.6B	↓ 2.71%

	Q4 FY24	Q/Q Change
Profit	$7.4B	↑ 12.2%

	Q1 FY25	Q/Q Change
Profit	$7.3B	↓ 1.13%

	Q2 FY25	Q/Q Change
Profit	$8.1B	↑ 9.95%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$8.1B	↑ 14.17%
Investing Cash Flow	$-9.8B	↑ 388.5%
Financing Cash Flow	$7.6B	↓ 315.59%

	FY20	Y/Y Change
Operating Cash Flow	$14.1B	↑ 74.19%
Investing Cash Flow	$-10.9B	↑ 11.15%
Financing Cash Flow	$-1.2B	↓ 115.1%

	FY21	Y/Y Change
Operating Cash Flow	$16.2B	↑ 15.34%
Investing Cash Flow	$-538.0M	↓ 95.05%
Financing Cash Flow	$-16.2B	↑ 1309.56%

	FY22	Y/Y Change
Operating Cash Flow	$13.1B	↓ 19.38%
Investing Cash Flow	$-1.1B	↑ 97.4%
Financing Cash Flow	$-17.0B	↑ 4.55%

	FY23	Y/Y Change
Operating Cash Flow	$13.9B	↑ 6.08%
Investing Cash Flow	$-2.3B	↑ 116.1%
Financing Cash Flow	$-9.4B	↓ 44.49%

	FY24	Y/Y Change
Operating Cash Flow	$15.2B	↑ 9.6%
Investing Cash Flow	$-21.4B	↑ 830.37%
Financing Cash Flow	$5.1B	↓ 154.45%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$2.8B	↓ 33.35%
Investing Cash Flow	$-19.6B	↑ 1357.5%
Financing Cash Flow	$14.6B	↑ 1414.37%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$2.3B	↓ 17.93%
Investing Cash Flow	$-1.3B	↓ 93.28%
Financing Cash Flow	$-4.0B	↓ 127.47%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$5.6B	↑ 140.37%
Investing Cash Flow	$-219.0M	↓ 83.4%
Financing Cash Flow	$-3.9B	↓ 4.25%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$4.4B	↓ 20.6%
Investing Cash Flow	$-196.0M	↓ 10.5%
Financing Cash Flow	$-1.6B	↓ 57.37%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$2.0B	↓ 55.98%
Investing Cash Flow	$-499.0M	↑ 154.59%
Financing Cash Flow	$-993.0M	↓ 39.52%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$3.9B	↑ 100.46%
Investing Cash Flow	$-473.0M	↓ 5.21%
Financing Cash Flow	$-1.8B	↑ 84.89%

Bristol-myers Squibb Co. Technicals Summary

Sell

Neutral

Buy

Bristol-myers Squibb Co. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Bristol-myers Squibb Co. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Bristol-myers Squibb Co.	1.96%	-21.37%	-5.71%	-30.24%	-24.63%
Eli Lilly And Company	-3.65%	-20.45%	-22.11%	138.51%	393.52%
Johnson & Johnson	4.9%	6.33%	6.84%	8.02%	14.37%
Merck & Co. Inc.	1.81%	-9.78%	-29.14%	-4.2%	-2.39%
Novo Nordisk A/s	12.11%	-38.12%	-59.21%	5.79%	69.87%
Abbvie Inc	9.81%	-0.55%	6.51%	53.37%	117.07%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Bristol-myers Squibb Co.	18.83	18.83	2.26	6.53	0.29	0.08	0.05	8.57
Eli Lilly And Company	47.84	47.84	1.06	22.83	0.86	0.17	0.01	20.38
Johnson & Johnson	18.88	18.88	1.07	10.85	0.3	0.08	0.03	32.6
Merck & Co. Inc.	12.95	12.95	0.83	8.93	0.35	0.13	0.04	19.57
Novo Nordisk A/s	14.55	14.55	1.67	24.84	0.79	0.22	0.03	37.82
Abbvie Inc	99.08	99.08	0.44	11.97	1.13	0.09	0.03	-0.1

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Bristol-myers Squibb Co.	Hold	$95.4B	-24.63%	18.83	10.58%
Eli Lilly And Company	Buy	$656.2B	393.52%	47.84	25.91%
Johnson & Johnson	Buy	$425.0B	14.37%	18.88	25.0%
Merck & Co. Inc.	Buy	$210.0B	-2.39%	12.95	25.79%
Novo Nordisk A/s	Buy	$247.1B	69.87%	14.55	35.61%
Abbvie Inc	Buy	$367.6B	117.07%	99.08	6.45%

Bristol-myers Squibb Co. Dividend announcements

Bristol-myers Squibb Co. Dividends September, 2025
In the quarter ending September,2025. Bristol-myers Squibb Co. has declared dividend of $0.62

About Bristol-myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Organization	Bristol-myers Squibb Co.
Employees	34100
CEO	Dr. Christopher S. Boerner Ph.D.
Industry	Health Technology

Key Management of Bristol-myers Squibb Co.

Name	Title
Dr. Christopher S. Boerner Ph.D.	CEO & Chairman
Mr. David V. Elkins	Executive VP & CFO
Ms. Karin Shanahan	Executive VP, Chief Supply Chain & Operations Officer
Mr. Samit Hirawat M.D.	Advisor
Mr. Greg Meyers	Executive VP and Chief Digital & Technology Officer
Ms. Kimberly M. Jablonski	Chief Compliance & Ethics Officer
Ms. Cari Gallman	Executive Vice President, General Counsel & Chief Policy Officer
Ms. Ahn Amanda Poole	Executive VP & Chief Human Resources Officer
Dr. Joseph J. Eiden Jr.	Head of Medical Affairs
Mr. Adam Lenkowsky	Executive VP & Chief Commercialization Officer

Important FAQs about investing in BMY Stock from India :

What is Bristol-myers Squibb Co. share price today?

Bristol-myers Squibb Co. share price today is $46.94 as on August 30, 2025 at 12:43 am IST. Bristol-myers Squibb Co. share today touched a day high of $47.32 and a low of $46.84.

What is the 52 week high and 52 week low for Bristol-myers Squibb Co. share?

Bristol-myers Squibb Co. share touched a 52 week high of $63.33 and a 52 week low of $42.96. Bristol-myers Squibb Co. stock price today i.e. August 30, 2025 at 12:43 am IST is trending at $46.94, lower by 25.88% versus the 52 week high.

How to invest in Bristol-myers Squibb Co. Stock (BMY) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Bristol-myers Squibb Co. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Bristol-myers Squibb Co. Shares that will get you 0.0320 shares as per Bristol-myers Squibb Co. share price of $46.94 per share as on August 30, 2025 at 12:43 am IST.

What is the minimum amount required to buy Bristol-myers Squibb Co. Stock (BMY) from India?

Indian investors can start investing in Bristol-myers Squibb Co. (BMY) shares with as little as ₹88.286 or $1 (as of August 29, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Bristol-myers Squibb Co. stock (as per the Rupee-Dollar exchange rate as on August 29, 2025). Based on Bristol-myers Squibb Co. share’s latest price of $46.94 as on August 30, 2025 at 12:43 am IST, you will get 0.2130 shares of Bristol-myers Squibb Co.. Learn more about fractional shares .

What are the returns that Bristol-myers Squibb Co. has given to Indian investors in the last 5 years?

Bristol-myers Squibb Co. stock has given -24.63% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?